Global expansion of the CDMO business through the acquisition of WuXi Biologics' German plant
First written in FY2025. 2 of 4 entries say "Achieved", first in FY2026-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AchievedAnnual report
「By using the pharmaceutical product manufacturing plant acquired in this transaction as the Terumo Group's first overseas CDMO production site, we will expand production capacity, strengthen our global capabilities, and accelerate the global development of our CDMO business.」
The acquisition of the Leverkusen plant in Germany was completed on 30 September 2025, and the plant was integrated into the business as the Company's first overseas CDMO production base. - 2026-05-15Cited as achievedEarnings
「By using the pharmaceutical product manufacturing plant acquired in this transaction as the Terumo Group's first overseas CDMO production site, we will expand production capacity, strengthen our global capabilities, and accelerate the global development of our CDMO business.」
The full-year disclosure cited the purpose of acquiring the Leverkusen plant in Germany and the plan to use it as the Group's first overseas CDMO production site. - FY2026-H1AchievedAnnual report
「Under this agreement, the acquisition was completed on 30 September 2025.」
The Company completed the acquisition of WuXi Biologics' drug product manufacturing plant in Leverkusen, Germany, on 30 September 2025, acquiring its first overseas CDMO production base. - FY2025First statedAnnual report
「The Group agreed to acquire, for €150 million (approximately ¥24.6 billion), the drug product manufacturing plant in Leverkusen, Germany, owned by WuXi Biologics, a contract development and manufacturing organisation (CDMO), and entered into a transfer agreement on 14 May 2025. The acquisition is expected to be completed in the fiscal year ending March 2026.」
The Company entered into an agreement to acquire a drug product manufacturing plant in Germany for €150 million as part of the globalisation of its CDMO business. Completion is scheduled for the fiscal year ending March 2026, and the acquisition is intended to strengthen production capacity and global capabilities as the Company's first overseas CDMO production base.